首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

NUCLEAR MEDICINE AND BIOLOGY
ISSN：0969-8051

NUCLEAR MEDICINE AND BIOLOGY

NUCL MED BIOL
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：一般,3-8周
新锐分区：医学4区
年发文量：62
影响因子：3
JCR分区：Q2

基本信息

《核医学与生物学》出版了涉及放射性药物科学各个方面的原创研究：合成、体外和离体研究、通过解剖或成像进行的体内生物分布、放射性药物学、放射性药物学和新靶向放射性示踪剂的转化临床研究。目标对未满足的临床需求的重要性应是首要考虑因素。如果一种新的放射性药物的合成在没有体外或体内数据的情况下提交，那么必须强调化学的独特性。这些多学科研究应该验证定位机制，无论探针是基于与受体、酶、肿瘤抗原还是其他明确的靶点的结合。研究的目的应是评价化学和放射性药物特性如何影响药代动力学、药效学或治疗效果。理想情况下，该研究将解决探针对疾病或治疗变化的敏感性，尽管仅验证机制的研究是可接受的。放射性药物学实践，涉及制备、自动化、质量控制、分配和适用于人类放射性药物的资格和管理的法规问题，是开发过程的一个重要方面，但只有在研究对实地有重大影响的情况下才能这样做。对治疗性放射性药物主题的贡献也是适当的，前提是标记化合物定位的特异性和治疗性影响已经得到解决。
0969-8051SCIE/Scopus收录
3
点击查看最新影响趋势>
2.8
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学
4区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
SCIE
Q2
59/213
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
SCIE
Q1
45/213
82
62
点击查看年发文量趋势图>
10%容易一般,3-8周-医学-核医学
6.7%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
100.00%30.63%-
CiteScore：6.90
SJR：0.742
SNIP：0.969
学科类别分区排名百分位
大类：Medicine
小类：Radiology, Nuclear Medicine and Imaging
Q1
41 / 346
大类：Medicine
小类：Cancer Research
Q2
77 / 233
大类：Medicine
小类：Molecular Medicine
Q2
62 / 177

期刊高被引文献

Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.003
An improved automated one-pot synthesis of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) based on a purification by cartridges.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.05.006
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.04.005
Somatostatin receptor targeting with hydrophilic [99mTc/186Re]Tc/Re-tricarbonyl NODAGA and NOTA complexes.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.04.004
Mini-review: Targeted radiopharmaceuticals incorporating reversible, low molecular weight albumin binders.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.006
Rapid and automated production of [68Ga]gallium chloride and [68Ga]Ga-DOTA-TATE on a medical cyclotron.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.07.005
A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.007
Development of [18F]FAMTO: A novel fluorine-18 labelled positron emission tomography (PET) radiotracer for imaging CYP11B1 and CYP11B2 enzymes in adrenal glands
来源期刊：Nuclear Medicine and BiologyDOI：10.1016/j.nucmedbio.2018.11.002
Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.11.005
Comparison of 68Ga-labeled RGD mono- and multimers based on a clickable siderophore-based scaffold.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.09.002
Accuracy of [68Ga]Ga-RM2-PET/CT for diagnosis of primary prostate cancer compared to histopathology.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.009
68Ga-labelled NOTA-RGD-GE11 peptide for dual integrin and EGFR-targeted tumour imaging.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2018.11.003
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.05.004
Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT1B receptors.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.005
A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing 89Zr - In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.12.009
68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.04.003
Synthesis and preclinical evaluation of the CRTH2 antagonist [11C]MK-7246 as a novel PET tracer and potential surrogate marker for pancreatic beta-cell mass.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.04.002
On-cartridge preparation and evaluation of 68Ga-, 89Zr- and 64Cu-precursors for cell radiolabelling.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.04.001
Improved production of 76Br, 77Br and 80mBr via CoSe cyclotron targets and vertical dry distillation.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.09.001
Evaluation of [18F]pitavastatin as a positron emission tomography tracer for in vivo organic transporter polypeptide function.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.08.001
Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.08.006
Design, synthesis and evaluation of 111In labeled DOTA-conjugated tetrapeptides having high affinity and selectivity for mu opioid receptors.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.02.001
Novel methods for the quantification of toxic, residual phase transfer catalyst in fluorine-18 labeled radiotracers.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.07.008
Imaging assessment of cardioprotection mediated by a dodecafluoropentane oxygen-carrier administered during myocardial infarction.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.004
In vivo imaging characterization and anticancer efficacy of a novel HER2 affibody and pemetrexed conjugate in lung cancer model.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2018.11.004
High-throughput radio-TLC analysis.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.12.003
Improved stability of a novel fluorine-18 labeled TCO analogue for pretargeted PET imaging.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.11.001
Evaluation of [18F]FDG/[18F]FLT/[18F]FMISO-based micro-positron emission tomography in detection of liver metastasis in human colorectal cancer.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.07.004
Sex-differences in [68Ga]Ga-DOTANOC biodistribution.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.08.005
Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.11.002
Synthesis, characterization and biological studies of rhenium, technetium-99m and rhenium-188 pentapeptides.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2018.11.001
PET [11C]acetate is also a perfusion tracer for kidney evaluation purposes.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.08.004
Synthesis of 11C-labeled DNA polymerase-β inhibitor 5-methoxyflavone and PET/CT imaging thereof.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.10.005
Synthesis and evaluation of 6-[18F]fluoro-3-(pyridin-3-yl)-1H-indole as potential PET tracer for targeting tryptophan 2, 3-dioxygenase (TDO).
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.12.007
Preparation of [177Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.11.003
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.05.003
VMAT2 imaging agent, D6-[18F]FP-(+)-DTBZ: Improved radiosynthesis, purification by solid-phase extraction and characterization.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.07.002
Targeting phosphatidylethanolamine and phosphatidylserine for imaging apoptosis in cancer.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.10.002
Development of a 18F-labeled PET radioligand for imaging 5-HT1B receptors: [18F]AZ10419096.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.10.003
Blood and urine analyses after radioembolization of liver malignancies with [166Ho]Ho-acetylacetonate-poly(l-lactic acid) microspheres.
来源期刊：Nuclear medicine and biologyDOI：10.1016/J.NUCMEDBIO.2019.03.001
Pre-labelling versus direct labelling of anthrax proteins for imaging of matrix metalloproteinases activity using DOTA-GA.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.07.007
Influence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.12.001
Synthesis of N-(6-[18F]Fluoropyridin-3-yl)glycine as a potential renal PET agent.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.09.004
Synthesis and evaluation of zirconium-89 labelled and long-lived GLP-1 receptor agonists for PET imaging.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.11.006
In vitro cytotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.12.004
Radiation induced oxidation of [18F]fluorothia fatty acids under cGMP manufacturing conditions.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.11.004
Development of a thin layer chromatography method for plasma correction of [18F]-fluoromethylcholine metabolites in positron emission tomography quantification studies in humans.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.08.003
Optimization of solid-phase extraction (SPE) in the preparation of [18F]D3FSP: A new PET imaging agent for mapping Aβ plaques.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.05.002
Synthesis and evaluation of 99mTc-analogues of [123/131I]mIBG prepared via [99mTc][Tc(CO)3(H2O)3]+ synthon for targeting norepinephrine transporter.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.01.001
Fluselenamyl: Evaluation of radiation dosimetry in mice and pharmacokinetics in brains of non-human primate.
来源期刊：Nuclear medicine and biologyDOI：10.1016/j.nucmedbio.2019.10.004

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

ACSMS HEALTH & FITNESS JOURNAL封面

ACSMS HEALTH & FITNESS JOURNAL

学科领域：医学
影响因子：1.8
中科院分区： 4区
ACTA BIOQUIMICA CLINICA LATINOAMERICANA封面

ACTA BIOQUIMICA CLINICA LATINOAMERICANA

学科领域：医学
影响因子：0.1
中科院分区： 4区
Acta Cardiologica Sinica封面

Acta Cardiologica Sinica

学科领域：医学
影响因子：1.8
中科院分区： 4区
Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca封面

Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca

学科领域：医学
影响因子：0.4
中科院分区： 4区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学
4区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学
4区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学
4区
否
否